Vairavan Latha 4

What Happened
CFO Vairavan Latha reported a sale of 1,341 shares of Arcutis Biotherapeutics common stock on May 4, 2026. The filing shows a weighted-average sale price of $23.61, for total proceeds of approximately $31,662. The Form 4 indicates the sale was to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Key Details

• Transaction date: 2026-05-04 (reported on Form 4 filed 2026-05-06) — filed within the typical 2-business-day window for Form 4s.
• Transaction type: Sale (S) — reported as open market/private sale; sale was for tax withholding (Footnote F1).
• Price: weighted-average $23.61; shares sold in multiple trades at prices ranging $23.16 to $23.93 (Footnote F2). Reporting person offers to provide per-price breakdown on request.
• Shares sold: 1,341; proceeds ≈ $31,662.
• Shares owned after transaction: Not disclosed in this filing.

Context
This sale was a tax-withholding sale tied to RSU vesting, a common and routine form of insider sale that does not necessarily indicate a change in the insider’s view of the company. No options were exercised and no 10b5-1 plan or late filing is indicated in this Form 4.